We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

6 hedge funds and large institutions have $15.3M invested in Hepion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

354% more capital invested

Capital invested by funds: $3.38M → $15.3M (+$12M)

100% more funds holding

Funds holding: 3 → 6 (+3)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$2.02M
2
EI
EAM Investors
California
+$1.01M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.01M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
TCIM
TIAA CREF Investment Management
New York
-$1.01M
2
LWM
LBA Wealth Management
Florida
-$15K
3
JFA
JNBA Financial Advisors
Minnesota
-$1K
4
S
SignatureFD
Georgia
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
1
TIAA CREF Investment Management
New York
$4.41M -$1.01M -1 -50%
EI
2
EAM Investors
California
$3.4M +$1.01M +1 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.23M +$1.01M +1 +50%
TA
4
Teachers Advisors
New York
$1.82M – – –
HighTower Advisors
5
HighTower Advisors
Illinois
$1.26M +$2.02M +2 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$416K +$1.01M +1 New
Morgan Stanley
7
Morgan Stanley
New York
$333K – – –
JP Morgan Chase
8
JP Morgan Chase
New York
$240K – – –
PFS
9
Prospera Financial Services
Texas
$236K – – –
CS
10
Credit Suisse
Switzerland
$188K – – –
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
$158K – – –
Barclays
12
Barclays
United Kingdom
$145K – – –
Northern Trust
13
Northern Trust
Illinois
$117K – – –
VKH
14
Virtu KCG Holdings
New York
$109K – – –
Russell Investments Group
15
Russell Investments Group
United Kingdom
$72K – – –
Bank of New York Mellon
16
Bank of New York Mellon
New York
$26K – – –
BFA
17
BlackRock Fund Advisors
California
$23K – – –
Cambridge Investment Research Advisors
18
Cambridge Investment Research Advisors
Iowa
$23K – – –
BA
19
BlackRock Advisors
Delaware
$22K – – –
Goldman Sachs
20
Goldman Sachs
New York
$20K – – –
LPL Financial
21
LPL Financial
California
$19K – – –
TSS
22
Two Sigma Securities
New York
$18K – – –
BIT
23
BlackRock Institutional Trust
California
$13K – – –
FFA
24
First Foundation Advisors
California
$12K – – –
Wells Fargo
25
Wells Fargo
California
$8K – – –
1
2

HEPA Hedge Fund Activity: Q4 2016 in Review

6 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2016, worth a combined $15.3M — up 354% from $3.38M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new HEPA positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was HighTower Advisors, opening a new position worth an estimated $2.02M. The largest seller was TIAA CREF Investment Management, cutting an estimated $1.01M.

  • 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2016, up from 3 in Q3 2016.
  • Funds reported $15.3M of Hepion Pharmaceuticals stock for Q4 2016, up 354% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q4 2016 and 0 closed out, a net change of +3 holders.
  • The largest Hepion Pharmaceuticals buyer in Q4 2016 was HighTower Advisors, an estimated $2.02M added.
  • The largest Hepion Pharmaceuticals seller in Q4 2016 was TIAA CREF Investment Management, an estimated $1.01M sold.

Based on aggregated 13F filings for Q4 2016.